Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

doi:10.3748/wjg.v27.i23.3327

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 23

This Article

(232)

(245)

(0)

(9)

(1)

(5925)

(5)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Basic Study

World J Gastroenterol. Jun 21, 2021; 27(23): 3327-3341
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3327

Table 2 Relationship between tuftelin 1 and clinicopathological characteristics in hepatocellular carcinoma patients

Group	n	TUFT1 expression		Pearson χ²	P value
Group	n	Low	High	Pearson χ²	P value
AFP (ng/mL)				2.901	0.089
< 20	28	18	10
≥ 20	104	48	56
HBsAg				3.300	0.069
Neg.	12	9	3
Pos.	120	57	63
HBeAg				4.080	0.043
Neg.	87	49	38
Pos.	45	17	28
Tumor size (cm)				9.388	0.002
< 3	26	20	6
≥ 3	106	46	60
Differentiation degree				3.013	0.083
Well-Med.	19	13	6
Poor	113	53	60
Vascular invasion				14.885	< 0.001
With	58	18	40
Without	74	48	26
Ascites				5.940	0.015
With	32	10	22
Without	100	56	44
TNM staging				13.516	< 0.001
I-II	59	40	19
III-IV	73	26	47

AFP: Alpha-fetoprotein; HBeAg: Hepatitis B virus e antigen; HBsAg: Hepatitis B virus surface antigen; HCC: Hepatocellular carcinoma; Neg: Negative expression; Pos: Positive expression; TUFT1: Tuftelin 1.

Full Size Table

Citation: Wu MN, Zheng WJ, Ye WX, Wang L, Chen Y, Yang J, Yao DF, Yao M. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth. World J Gastroenterol 2021; 27(23): 3327-3341
URL: https://www.wjgnet.com/1007-9327/full/v27/i23/3327.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i23.3327

Wu MN, Zheng WJ, Ye WX, Wang L, Chen Y, Yang J, Yao DF, Yao M. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth. World J Gastroenterol 2021; 27(23): 3327-3341 [PMID: 34163115 DOI: 10.3748/wjg.v27.i23.3327]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.